Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for PNALD
NCT00826020Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- May 2009
- Primary completion
- Oct 2017
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD) and cholestasis, sponsored by University of Nebraska. Primary endpoint: Number of Patients With Progression to Small Bowel Transplantation at 5.5 years. Started May 2009; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)cholestasis
Beyond the preview
Go deeper on NCT00826020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826020.